Edwards Lifesciences Corp (EW) concluded Q3 2025 with significant
revenue growth and surpassed Wall Street estimates. Internally, several firms, including Mccarter Private Wealth Services LLC and Spire Wealth Management, shifted their positions within the company. External analysts show varied sentiments, yet the majority, including Mizuho, maintain an
Outperform recommendation. Respectively, RBC Capital, Citigroup, Barclays, Royal Bank Of Canada, and Goldman Sachs raised their price target due to expected price appreciation. The company reported a decrease in Q3 profit, still beating estimates. Q3 earnings showed a rise in crucial metrics paired with strong growth. Several firms raised their holdings in EW, and Edwards Lifesciences have updated their Q4 revenue and adjusted EPS ranges. Stock performance reflected this activity, with shares trading flat despite Q3 beats. Lastly, the company's future looks optimistic following successful long-term data for the
SAPIEN Valve platform and the introduction of new potential paradigm-shifting trials.
Edwards Lifesciences Corp EW News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Sat, 01 Nov 2025 20:15:34 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor -3
